Protection by design
MEVOX combines in-house expertise with world class partnerships in antigen design and vaccine development. We leverage this cutting-edge vaccine innovation and translational expertise to bring established vaccines into the 21st century and address significant unmet needs.
MEVOX
MEVOX brings vaccinology into the 21st century. We translate cutting-edge molecular characterization, design and engineering into conformationally precise and optimized protein vaccines. These induce 10-100 times higher neutralising antibody levels than existing vaccines, also showing sterilizing and durable immunity. We embed this scientific excellence in partnerships with world leaders on our target diseases with antigen design and translation. Our goal is global health impact through protection by design.
Board
Executives
Advisors
Board
Stephanie Monaghan O’Brien and Guillaume Stewart-Jones are part of the board.
Executives
Advisors
and our investors
Our Values
Vaccine Architects Engineering
Protection by design
Protection by design